Cipla’s US Subsidiary Recalls Nilotinib Capsules Following Manufacturing Specification Issue

A US-based arm of Indian pharmaceutical company Cipla has initiated a voluntary recall of certain batches of a generic anti-cancer medication in the United States. The recall follows a manufacturing specification concern identified in the affected capsules.

According to the US health regulator, the action has been classified as a Class III recall, indicating that the issue is unlikely to lead to serious health consequences but requires corrective action.

Recall Initiated by Cipla’s US Unit

Cipla USA, Inc, headquartered in Warren, New Jersey, has announced the recall of specific batches of Nilotinib capsules distributed in the United States.

The recall involves capsules in two strengths including 150 mg and 200 mg.

According to the U.S. Food and Drug Administration (USFDA), the action affects more than 400 cartons of the medication. The recall was carried out after certain batches failed to meet specified tablet or capsule quality standards.

Reason Behind the Recall

The USFDA’s Enforcement Report stated that the recall was initiated due to failed tablet or capsule specifications in the affected lots.

Two batches were involved in the recall including 271 cartons from one batch and 164 cartons from another batch

The company began the voluntary recall on 18 February 2026 as part of corrective measures to remove the affected products from distribution.

Classification of the Recall

The USFDA categorised the action as a Class III recall. This classification is generally applied when the use of a product that does not comply with manufacturing standards is unlikely to cause serious health issues.

However, such recalls are undertaken to ensure regulatory compliance and maintain quality standards within pharmaceutical supply chains.

Role of Nilotinib in Cancer Treatment

Nilotinib is a medication used in certain cancer treatments. It works by blocking the activity of abnormal proteins that stimulate the multiplication of cancer cells.

By inhibiting this signalling process, the drug helps slow or stop the growth and spread of cancer cells. The medication is commonly prescribed as part of targeted therapy in specific types of blood cancers.

India’s Presence in the US Pharmaceutical Market

India continues to play an important role in supplying medicines to the United States. The country hosts a large number of pharmaceutical manufacturing facilities that comply with USFDA standards.

Indian pharmaceutical companies supply a significant share of medicines used by patients in the US. Industry data indicates that around four out of ten prescriptions filled in the US in 2022 were supplied by Indian drug manufacturers.

Cipla Share Price Performance

Shares of Cipla were trading at around ₹1,322.90 on 9 March 2026, slightly above the previous closing price of ₹1,321.20, indicating limited movement during the session. The stock opened at ₹1,309.00 and moved within a range during the day, touching a high of ₹1,329.80 and a low of ₹1,292.70

Read More: Fairfax, OMERS to extend IPO timeline ofBangalore airport holding company.

Conclusion

The recall initiated by Cipla’s US subsidiary highlights the regulatory oversight governing pharmaceutical products in international markets. Although the USFDA classified the action as a Class III recall with limited health risk, the step reflects quality control procedures followed within the industry. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.